Business
BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference
PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therape...
About this update from Briacell Therapeutics Corp
[{"type":"text","content":"BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference\n\n\n\n PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting three posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place from April 25\n \n th\n \n – 30\n \n th\n \n at McCormick Place Convention Center, Chicago, IL. The details are listed below. The abstracts will be published in the online\n \n Proceedings of the AACR\n \n .\n \n\n\n Poster 1:\n \n\n\n Title:\n \n\n Bria-ABC\n \n\n\n 1\n \n\n vs physician choice in late-stage MBC; early biomarker correlates of the randomized registration trial\n \n\n Session Title:\n \n Late-Breaking Research: Clinical Research 4\n \n\n Session Date and Time:\n \n 4/30/2025 9:00 AM – 12:00 PM CST\n \n\n Location:\n \n Poster Section 49\n \n\n Poster\n \n Board Number: 14\n \n\n Abstract Presentation Number:\n \n LB408\n \n\n\n Poster 2:\n \n\n\n Title:\n \n Survival outcomes in a randomized phase 2 of\n \n Bria-IMT\n \n : An allogeneic whole cell cancer vaccine\n \n\n Session Title:\n \n Phase II and Phase III Clinical Trials\n \n\n Session Start:\n \n 4/28/2025 2:00 PM – 5:00 PM CST\n \n\n Location:\n \n Poster Section 50\n \n\n Poster Board Number:\n \n 18\n \n\n Abstract Presentation Number:\n \n CT100\n \n\n\n Poster 3:\n \n\n\n Title:\n \n Bria-OTS+: A versatile therapeutic platform for inducing anti-cancer immunity\n \n\n Session Category:\n \n Immunology\n \n\n Session Title:\n \n Vaccines, In Situ Vaccines, and Vaccine Combinations\n \n\n Session Date and Time:\n \n 4/28/2025 2:00 – 5:00 PM CST\n \n\n Location:\n \n Poster Section 39\n \n\n Poster Board Number:\n \n 29\n \n\n Published Abstract Number:\n \n 3553\n \n\n Following the presentation, copies of the posters will be made available at\n \n https://briacell.com/scientific-publications/\n \n .\n \n\n\n About BriaCell Therapeutics Corp.\n \n\n\n BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is a...